Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduction effect of the quantity of radiation exposure and contrast media by image support system in transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Tamai T, Taniyama O, Oda K, Kasai A, Ijyuin S, Sakae H, Onishi H, Tabu K, Kumagai K, Mawatari S, Moriuchi A, Uto H, Ido A. Tamai T, et al. Among authors: onishi h. J Gastroenterol Hepatol. 2018 May;33(5):1115-1122. doi: 10.1111/jgh.14012. Epub 2018 Feb 6. J Gastroenterol Hepatol. 2018. PMID: 28994147
Utility of percutaneous radiofrequency ablation alone or combined with transarterial chemoembolization for early hepatocellular carcinoma.
Tamai T, Oshige A, Tabu K, Tabu E, Ijyuin S, Sakae H, Onishi H, Muromachi K, Saisyoji A, Oda K, Kumagai K, Mawatari S, Moriuchi A, Sakurai K, Hori T, Ido A. Tamai T, et al. Among authors: onishi h. Oncol Lett. 2017 Sep;14(3):3199-3206. doi: 10.3892/ol.2017.6476. Epub 2017 Jun 23. Oncol Lett. 2017. PMID: 28927066 Free PMC article.
Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco-regional control?
Tamai T, Kumagai K, Sakae H, Onishi H, Tabu K, Tabu E, Muromachi K, Saishoji A, Oda K, Mawatari S, Moriuchi A, Sakurai K, Ido A. Tamai T, et al. Among authors: onishi h. Mol Clin Oncol. 2017 Dec;7(6):1135-1141. doi: 10.3892/mco.2017.1434. Epub 2017 Oct 2. Mol Clin Oncol. 2017. PMID: 29285389 Free PMC article.
Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".
Kikuchi T, Takeuchi Y, Nouso K, Kariyama K, Kuwaki K, Toshimori J, Iwado S, Moriya A, Hagihara H, Takabatake H, Tada T, Yasunaka T, Sakata M, Sue M, Miyake N, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A, Otsuka M. Kikuchi T, et al. Among authors: onishi h. Liver Int. 2024 May 8. doi: 10.1111/liv.15964. Online ahead of print. Liver Int. 2024. PMID: 38717049 No abstract available.
1,469 results